|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 73.35 EUR | +0.34% |
|
-5.73% | -11.33% |
| 08/05 | A lot of noise, little impact? | |
| 08/05 | Berenberg Calls for More Acquisitions from Sanofi; Estimates Updated | MT |
Company Valuation: Sanofi
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,11,194 | 1,12,665 | 1,12,549 | 1,16,968 | 1,00,655 | 87,736 | - | - |
| Change | - | 1.32% | -0.1% | 3.93% | -13.95% | -12.83% | - | - |
| Enterprise Value (EV) 1 | 1,21,177 | 1,19,102 | 1,20,342 | 1,25,740 | 1,11,663 | 99,998 | 98,134 | 97,427 |
| Change | - | -1.71% | 1.04% | 4.49% | -11.2% | -10.45% | -1.86% | -0.72% |
| P/E ratio | 17.8x | 16.7x | 20.8x | 20.4x | 12.9x | 10.7x | 9.92x | 8.62x |
| PBR | 1.62x | 1.5x | 1.52x | 1.51x | 1.41x | 1.18x | 1.12x | 1.05x |
| PEG | - | 2.07x | -1.1x | 3.14x | 0.3x | 1.51x | 1.31x | 0.6x |
| Capitalization / Revenue | 2.94x | 2.62x | 2.61x | 2.85x | 2.31x | 1.88x | 1.77x | 1.69x |
| EV / Revenue | 3.21x | 2.77x | 2.79x | 3.06x | 2.56x | 2.14x | 1.98x | 1.87x |
| EV / EBITDA | 9.95x | 8.14x | 8.44x | 9.76x | 8.22x | 6.94x | 6.44x | 5.86x |
| EV / EBIT | 11.3x | 9.13x | 9.5x | 11.1x | 9.19x | 7.54x | 7.02x | 6.41x |
| EV / FCF | 15x | 14x | 14.2x | 21.1x | 13.8x | 11.6x | 10.6x | 9.33x |
| FCF Yield | 6.68% | 7.12% | 7.04% | 4.74% | 7.24% | 8.65% | 9.43% | 10.7% |
| Dividend per Share 2 | 3.33 | 3.56 | 3.76 | 3.92 | 4.12 | 4.288 | 4.523 | 4.821 |
| Rate of return | 3.76% | 3.96% | 4.19% | 4.18% | 4.98% | 5.87% | 6.19% | 6.6% |
| EPS 2 | 4.97 | 5.37 | 4.31 | 4.59 | 6.4 | 6.852 | 7.372 | 8.481 |
| Distribution rate | 67% | 66.3% | 87.2% | 85.4% | 64.4% | 62.6% | 61.4% | 56.8% |
| Net sales 1 | 37,761 | 42,997 | 43,070 | 41,081 | 43,626 | 46,717 | 49,576 | 52,049 |
| EBITDA 1 | 12,183 | 14,627 | 14,259 | 12,889 | 13,583 | 14,418 | 15,249 | 16,633 |
| EBIT 1 | 10,714 | 13,040 | 12,670 | 11,343 | 12,149 | 13,261 | 13,983 | 15,192 |
| Net income 1 | 6,223 | 6,720 | 5,400 | 5,744 | 7,813 | 8,147 | 8,815 | 10,147 |
| Net Debt 1 | 9,983 | 6,437 | 7,793 | 8,772 | 11,008 | 12,262 | 10,398 | 9,691 |
| Reference price 2 | 88.58 | 89.84 | 89.76 | 93.74 | 82.72 | 73.10 | 73.10 | 73.10 |
| Nbr of stocks (in thousands) | 12,55,293 | 12,54,060 | 12,53,891 | 12,47,793 | 12,16,810 | 12,00,220 | - | - |
| Announcement Date | 04/02/22 | 03/02/23 | 01/02/24 | 30/01/25 | 29/01/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 10.67x | 2.14x | 6.94x | 5.87% | 10TCr | ||
| 27.83x | 10.14x | 20.87x | 0.72% | 85TCr | ||
| 23.65x | 5.46x | 14.84x | 2.41% | 53TCr | ||
| 24.57x | 6.1x | 12.42x | 3.41% | 36TCr | ||
| 16.67x | 4.18x | 10.31x | 3.18% | 32TCr | ||
| 22.88x | 4.76x | 13.54x | 1.83% | 28TCr | ||
| 20.12x | 5.43x | 13.2x | 3.09% | 28TCr | ||
| 49.69x | 4.63x | 17.34x | 2.99% | 28TCr | ||
| 13.18x | 4.82x | 9.89x | 3.84% | 20TCr | ||
| 21.33x | 5.83x | 10.12x | 3.04% | 18TCr | ||
| Average | 23.06x | 5.35x | 12.95x | 3.04% | 33.79TCr | |
| Weighted average by Cap. | 24.74x | 6.33x | 14.83x | 2.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- SAN Stock
- Valuation Sanofi
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















